Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 10 of 10 matching drugs for OGFOD1 — including drugs targeting any of its 80 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine OGFOD1 Direct 1
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, ascorbic acid OGFOD1 Direct 1
temozolomide, radiation therapy, ascorbic acid OGFOD1 Direct 1
digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin ATP1A1 SSL via ATP1A1 1
acetyldigitoxin ATP1A1 SSL via ATP1A1 yes 0
deslanoside ATP1A1 SSL via ATP1A1 yes 0
digitoxin ATP1A1 SSL via ATP1A1 yes 0
digoxin ATP1A1 SSL via ATP1A1 yes 0
metformin NDUFA8 SSL via NDUFA8 yes 0
metformin hydrochloride NDUFA8 SSL via NDUFA8 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.